| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 158 |
| 1 | PEMBROLIZUMAB | 150 |
| 2 | IPILIMUMAB | 67 |
| 3 | CARBOPLATIN | 54 |
| 4 | PACLITAXEL | 33 |
| 5 | PEMETREXED DISODIUM | 31 |
| 6 | PACLITAXEL (AIBUMIN-BOUND) | 28 |
| 7 | CISPLATIN | 27 |
| 8 | DURVALUMAB | 23 |
| 9 | ACETAMINOPHEN | 22 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE | 1 | 0.0152 |
| 1 | NALDEMEDINE | 5 | 0.0030 |
| 2 | FLURANDRENOLIDE | 1 | 0.0030 |
| 3 | CEMIPLIMAB-RWLC | 5 | 0.0024 |
| 4 | CROTAMITON | 1 | 0.0016 |
| 5 | NIVOLUMAB | 158 | 0.0016 |
| 6 | TREMELIMUMAB | 7 | 0.0016 |
| 7 | IPILIMUMAB | 67 | 0.0015 |
| 8 | VONOPRAZAN FUMARATE | 12 | 0.0015 |
| 9 | PEMBROLIZUMAB | 150 | 0.0014 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 319 | 0.0032 |
| 1 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 74 | 0.0015 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 24 | 0.0011 |
| 4 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 4 | 0.0005 |
| 5 | Lipid Emulsion [EPC] | 1 | 0.0004 |
| 6 | Platinum-based Drug [EPC] | 99 | 0.0004 |
| 7 | Orexin Receptor Antagonist [EPC] | 6 | 0.0003 |
| 8 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 9 | Bile Acid [EPC] | 6 | 0.0003 |